ISTH interim guidance on recognition and management of coagulopathy in COVID‐19

Affiliations: 1 Department of Haematology, Manchester University Hospitals, Oxford road, Manchester, United Kingdom, 2 Tongji hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China, 3 Department of Acute and Critical Care Medicine, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan, 4 University of Milan Bicocca, Dept of Medicine and Surgery; Hospital Papa Giovanni, XXIII, Bergamo; Italy, 5 ASST Santi Paolo e Carlo, Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milan. ITALY, 6 Department of Medicine and Cardio-metabolic Programme-NIHR UCLH/UCL BRC, University College London Hospitals NHS Foundation Trust, London, United Kingdom, 7 Director of Programs and Education, International Society on Thrombosis and Haemostasis 8 Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

[1]  C. Eastin,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The Journal of Emergency Medicine.

[2]  Mario Plebani,et al.  Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis , 2020, Clinica Chimica Acta.

[3]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[4]  Dengju Li,et al.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[5]  Yuqiong Yang,et al.  Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics , 2020, The Lancet Respiratory Medicine.

[6]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[7]  T. van der Poll,et al.  Diagnosis and management of sepsis‐induced coagulopathy and disseminated intravascular coagulation , 2019, Journal of thrombosis and haemostasis : JTH.

[8]  J. Thachil,et al.  New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey , 2017, BMJ Open.

[9]  P. Libby,et al.  More than an anticoagulant: Do heparins have direct anti-inflammatory effects? , 2016, Thrombosis and Haemostasis.

[10]  Christopher W Seymour,et al.  Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[11]  D. Cook,et al.  Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. , 2013, Chest.

[12]  J. Thachil,et al.  Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines , 2013, Journal of thrombosis and haemostasis : JTH.

[13]  M. Di Nisio,et al.  Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). , 2012, Thrombosis Research.

[14]  J. Thachil,et al.  Guidelines for the diagnosis and management of disseminated intravascular coagulation , 2009, British journal of haematology.

[15]  F B Taylor,et al.  Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation , 2001, Thrombosis and Haemostasis.

[16]  S. Lewis.  British Committee for Standards in Haematology , 1969 .